Research and Markets: Bronchitis Therapeutics Market is Forecast to Show Slow Growth until 2018 - Pipeline Assessment and Market Forecasts to 2018

DUBLIN--(BUSINESS WIRE)--Research and Markets(http://www.researchandmarkets.com/research/0d57e5/bronchitis_therape) has announced the addition of GlobalData's new report "Bronchitis Therapeutics - Pipeline Assessment and Market Forecasts to 2018" to their offering.

“Bronchitis Therapeutics - Pipeline Assessment and Market Forecasts to 2018”

GlobalData, the industry analysis specialist, has released its new report, Bronchitis Therapeutics - Pipeline Assessment and Market Forecasts to 2018. The report is an essential source of information and analysis on the global Bronchitis Therapeutics market. The report identifies the key trends shaping and driving the global Bronchitis Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Bronchitis Therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

GlobalData estimates that the global bronchitis therapeutics market was valued at $5,984m in 2010 and is forecast to grow at a Compound Annual Growth Rate (CAGR) of 1.9% to reach $6,931m by 2018. The current market is sub-divided into acute bronchitis and chronic bronchitis. The acute bronchitis market is mainly served by generic antibiotics such as azithromycin, clarithromycin, erythromycin, sulfamethoxazole and trimethoprim. The therapies for chronic bronchitis includes drug classes such as bronchodilators, inhaled corticosteroids and combination therapies. The bronchitis therapeutics market has registered high growth of 13.6% during 2005 to 2010.

Key Topics Covered:

• List of Tables and Figures
• Bronchitis Therapeutics - Introduction
• Bronchitis Therapeutics - Market Characterization
• Bronchitis Therapeutics - Competitive Assessment
• Bronchitis Therapeutics - Pipeline Assessment
• Bronchitis Therapeutics - Clinical Trials Mapping
• Bronchitis Therapeutics - Strategic Assessment
• Bronchitis Therapeutics - Future Players
• Bronchitis Therapeutics - Licensing and Partnership Deals
• Bronchitis Therapeutics - Appendix

Companies Mentioned:

• GlaxoSmithKline
• Novartis AG
• AstraZeneca
• Bronchitis Pipeline
• Merck & Co.
• Forest Laboratories, Inc.
• Boehringer Ingelheim GmbH
• Financial Overview
• Almirall, S.A.
• Orion Corporation
• Rottapharm Madaus
• Ache Laboratorios Farmaceuticos S/A

For more information visit http://www.researchandmarkets.com/research/0d57e5/bronchitis_therape